Epidarex Capital ("Epidarex"), an early-stage, transatlantic life science venture fund, today announced that its portfolio company, Harpoon Medical, Inc. ("Harpoon"), a pioneer in beating-heart repair for degenerative mitral regurgitation (DMR), has been acquired by Edwards Lifesciences for up to $250 million. Under the terms of the merger agreement, Edwards paid $100 million in cash for Harpoon at closing on December 1, 2017 with a potential for up to an additional $150 million in pre-specified milestone-driven payments.